Navigation Links
Human Pheromone Sciences Announces First Quarter Results
Date:5/14/2009

Current Period Results Impacted by Downturn in Worldwide Beauty Markets

SAN JOSE, Calif., May 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or the "Company") today announced results for the first quarter ended March 31, 2009. Net revenues of $165,000 represented a 38% decrease from the revenues of $266,000 in the prior year period, and resulted in a net loss of $181,000 ($0.04 per share) as compared with net loss of $63,000 ($0.02 per share) for the same period of 2008. At March 31, 2009, the Company reflected cash balances of $664,000 compared with $907,000 in cash at December 31, 2008, a $243,000 reduction in the quarter. There was no bank indebtedness at either period.

According to a Company spokesperson, "the revenue and cash declines were in line with the Company's internal forecasts, reflecting the extremely difficult overall adverse economic climate and the significant downturn in the worldwide Fragrance and Beauty Markets. We had anticipated the reduction of revenues on sales to our once largest fragrance and beauty-based company, and, as such, embarked upon a program to expand other potential markets for the use of our patented technology in other consumer product arenas. Some of the shortfall in the basic beauty area was offset by supply and royalty revenues received under our licensing agreement with Schwarzkopf & Henkel in the worldwide hair care and personal product markets. Pheromone purchases by our two primary licensees, increased by 79%, in anticipation of a new product launch in May 2009 by one of these companies. While the selling price of the pheromones is quite low compared to that of prior licensees, our newer agreements provide for royalties on licensee sales of products containing our patented technology. As such, we would anticipate an increase in royalty income in subsequent periods this year."

"Generating additional revenues under new licensing agreements will not only grow our business, but will reduce the effect of erratic purchasing patterns by one major licensee. In addition, while the Company is focusing on reducing expenditures, we continue to invest in maintaining our current patents and seeking such protection for our newest technology on a worldwide basis," the spokesperson indicated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                                 Tables follow



                          HUMAN PHEROMONE SCIENCES, INC.

                            Condensed Balance Sheets
                             (Dollars in thousands)

                                          March 31,             December 31,
                                            2009                    2008
                                            ----                    ----
                                         (Unaudited)
    Assets

    Cash and cash equivalents                   $664                    $907
    Accounts receivable                           61                      52
    Inventories, net                              51                      39
    Other current assets                          34                      58
    Property and equipment, net                    2                       2
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========

    Liabilities and shareholders' deficit

    Accounts payable                             $54                     $19
    Other current liabilities                    103                     131
    Deferred income - current                    270                     297
    Deferred income - non-current                265                     324
    Common stock                              21,056                  21,043
    Accumulated deficit                      (20,936)                (20,756)
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========



                          HUMAN PHEROMONE SCIENCES, INC.

                        Condensed Statements of Operations
                                   (Unaudited)
                   (Dollars in thousands, except per-share data)

                                            Three months ended March 31,
                                               2009               2008
                                              ------             ------

    Net revenues                                $165               $266
    Cost of goods sold                            65                 81
    Research and development                      25                 14
    Selling, general and administrative          257                244
                                              ------             ------

    Income (loss) from operations               (182)               (73)

    Other income                                   1                 11

    Provision for income taxes                     -                  1
                                              ------             ------

    Net income (loss)                          $(181)              $(63)
                                              ======             ======


    Income (loss) per share, basic            $(0.04)            $(0.02)
                                              ======             ======

    Income (loss) per share, fully diluted    $(0.04)            $(0.02)
                                              ======             ======

    Weighted average common shares
     Outstanding - Basic                       4,152              4,152
                                              ======             ======
    Weighted average common shares
     Outstanding - Fully diluted               4,152              4,152
                                              ======             ======

    Net income (loss) per share is based on the weighted average number of
    common shares and common equivalents outstanding during each period.
    Certain common stock equivalents are excluded when their effect would be
    anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Embryonic Stem Cells Repair Human Heart
2. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
3. Human Papilloma Virus vaccines may decrease chances of oral cancer
4. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
5. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
6. Toddler Study Proves Humans Outsmart Apes
7. Human C-reactive protein regulates myeloma tumor cell growth and survival
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. New class of RNA molecules may be important in human cancer
11. The Humana Foundation and Libraries for the Future Launch Health Literacy Pilot in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: